NCT00532974View on ClinicalTrials.gov

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)

PHASE1UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

April 30, 2008

Conditions
HIV Infections
Interventions
BIOLOGICAL

EP1090

Low dose

BIOLOGICAL

EP1090

High dose

Trial Locations (2)

80262

University of Colorado Health Sciences Center, Denver

90069

AIDS Research Alliance, West Hollywood

Sponsors

Lead Sponsor

Epimmune

Collaborators (1)

Pharmexa A/S
All Listed Sponsors
collaborator

Pharmexa A/S

INDUSTRY

collaborator

Pharmexa-Epimmune

UNKNOWN

lead

Epimmune

INDUSTRY

NCT00532974 - A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART) | Biotech Hunter | Biotech Hunter